AbbVie Inc (ABBV)vsArdent Health Partners, Inc. (ARDT)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
ARDT
Ardent Health Partners, Inc.
$8.68
+0.93%
HEALTHCARE · Cap: $1.32B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 877% more annual revenue ($62.82B vs $6.43B). ABBV leads profitability with a 5.8% profit margin vs 2.1%. ARDT trades at a lower P/E of 9.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ARDT
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ARDT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
2.1% margin — thin
Earnings declined 3.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 49/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., based in Nashville, Tennessee, is a leading healthcare organization committed to providing exceptional, patient-centered care via its robust network of hospitals and outpatient facilities. With a reputation for innovation and quality, Ardent boasts a diverse portfolio of acute care hospitals and is focused on developing healthcare solutions that address the unique needs of the communities it serves. Supported by a strong financial foundation and a strategic growth plan, the company is strategically positioned to expand healthcare access and enhance patient outcomes in an ever-evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?